IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
36.20
+0.19 (0.53%)
Jan 22, 2026, 4:00 PM EST - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 131 employees as of December 31, 2024. The number of employees increased by 7 or 5.65% compared to the previous year.
Employees
131
Change (1Y)
7
Growth (1Y)
5.65%
Revenue / Employee
$1,639,954
Profits / Employee
-$1,227,000
Market Cap
3.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 131 | 7 | 5.65% | 131 | 0 |
| Dec 31, 2023 | 124 | 21 | 20.39% | 124 | 0 |
| Sep 30, 2023 | 122 | 27 | 28.42% | 122 | 0 |
| Jun 30, 2023 | 116 | 25 | 27.47% | 116 | 0 |
| Mar 31, 2023 | 107 | 20 | 22.99% | 107 | 0 |
| Dec 31, 2022 | 103 | 22 | 27.16% | 103 | 0 |
| Sep 30, 2022 | 95 | 12 | 14.46% | 95 | 0 |
| Jun 30, 2022 | 91 | 16 | 21.33% | 91 | 0 |
| Mar 31, 2022 | 87 | 18 | 26.09% | 87 | 0 |
| Dec 31, 2021 | 81 | 19 | 30.65% | 81 | 0 |
| Sep 30, 2021 | 83 | 25 | 43.10% | 83 | 0 |
| Jun 30, 2021 | 75 | 29 | 63.04% | 75 | 0 |
| Mar 31, 2021 | 69 | 26 | 60.47% | 69 | 0 |
| Dec 31, 2020 | 62 | 15 | 31.91% | 62 | 0 |
| Sep 30, 2020 | 58 | 8 | 16.00% | 58 | 0 |
| Jun 30, 2020 | 46 | -10 | -17.86% | 46 | 0 |
| Mar 31, 2020 | 43 | -15 | -25.86% | 43 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Beam Therapeutics | 483 |
| Arcutis Biotherapeutics | 342 |
| Xenon Pharmaceuticals | 327 |
| Tarsus Pharmaceuticals | 323 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 181 |
| Liquidia | 170 |
| Viridian Therapeutics | 143 |
IDYA News
- 10 days ago - IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 18 days ago - IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - PRNewsWire
- 7 weeks ago - IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire
- 7 weeks ago - IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types - PRNewsWire